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500 kHZ intracavitary hyperthermia in the treatment of patients 
with cervical and endometrial cancer – preliminary results 
and treatment description
Norbert Piotrkowicz1, Jan Zieliƒski2, Jaros∏aw ¸yczek1, Piotr D´bicki3
The effectiveness of elevated temperature (hyperthermia) in cancer treatment is a well-known issue. However, due to techni-
cal problems with generating hyperthermia within the tumour and, at the same time, sparing the healthy tissues, in practice this
modality is not widely used.
M e t h o d.  Local hyperthermia was induced by a computer-controlled generator (500 kHz) with three amplifiers transmitting
energy to the lesion via a modified uterine brachytherapy applicator. Temperature was measured with 3 thermocouples.
Total treatment time was 60-90 minutes.
M a t e r i a l.  10 patients with cervical and endometrial cancer were enrolled into this study and 11 procedures were performed.
Prior to hyperthermia all patients were treated with external field irradiation to the pelvis to the dose of 45-46 Gy. Intracavitary
LDR/HDR brachytherapy (dose of 45 Gy/point “A” in two fractions) with colpostat used for the hyperthermia procedure was
than performed. 
Re s u l t s.  In all cases, except one, caused by equipment failure, biologically stable temperature was observed. No severe side
effects of treatment were observed. There was no need to terminate treatment due to high temperature intolerance.
Wewnàtrzjamowa hipertermia 500 kHz w leczeniu chorych na raka szyjki i trzonu macicy 
– opis metody i wst´pne wyniki
Terapeutyczne mo˝liwoÊci zastosowania podwy˝szonej temperatury w leczeniu nowotworów znane by∏y od dawna. TrudnoÊci
techniczne w uzyskaniu adekwatnej temperatury w guzie, z jednoczesnà ochronà tkanek zdrowych, sà jak dotàd podstawowym
czynnikiem, limitujàcym szersze praktyczne zastosowanie metody. 
M a t e r i a ∏  i  m e t o d y.  Do przeprowadzenia zabiegów zastosowano sterowany komputerowo generator i 3 wzmacniacze fal
radiowych o cz´stotliwoÊci 500 kHz, przekazujàcy chorym tkankom energi´ za pomocà zmodyfikowanego aplikatora (kolpo-
statu) Fletcher'a. Pomiar temperatury odbywa∏ si´ za pomocà zestawu trzech termopar. Praktyczny czas przeprowadzenia za-
biegu wynosi∏ 60-90 minut. Przeprowadzono 11 zabiegów u 10 chorych z rozpoznaniem raka szyjki macicy i trzonu macicy.
Przed rozpocz´ciem hipertermii wszystkie chore na raka szyjki poddane zosta∏y napromienieniu z pól zewn´trznych na obszar
miednicy ma∏ej do dawki 45-46 Gy. Zabieg hipertermii bezpoÊrednio poprzedza∏ Êródjamowà brachyterapi´ LDR/MDR
(dawka 45 Gy/punkt “A” w dwóch etapach), przeprowadzanà za pomocà tego samego kolpostatu. Po poinformowaniu
o charakterze zabiegu nagrzewania ka˝dorazowo uzyskiwano zgod´ chorej na jego przeprowadzenie. 
W y n i k i.  Poza jednym przypadkiem (awaria aparatu) u wszystkich leczonych uda∏o si´ uzyskaç stabilne w czasie terapeutycz-
ne wartoÊci temperatur, a w kilku przypadkach temperatury dochodzàce nawet do 48 C° by∏y dobrze tolerowane przez chore.
Nie stwierdzono ˝adnych powa˝niejszych objawów ubocznych zabiegów; nie zasz∏a koniecznoÊç ich przerwania ze wzgl´du na
brak tolerancji chorej.
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Introduction
The therapeutic effects of high temperature has been
widely known since ancient times. Hippocrates mentions
it to be as effective as pharmacology and surgery [1]. In
1866 spontaneous regression of a soft tissue sarcoma was
described in a patient with fever caused by erysipelas. In
1893 Coley tried to adapt high temperature therapy into
practice – he caused fever in patients with cancer by giving
them Streptococcus toxin [2]. Progress in surgical tech-
niques, incorporation of cytostatics into oncological ther-
apy and the development of ionizing radiation have over-
shadowed hyperthermia for many years. The interest in it
revived again in the 1970-s.
Biological background
High temperature affects both the cellular and the tis-
sue level. Its cytostatic effect reflects damage to cell mem-
brane, contractile fibre, cell skeleton, lyzosomes, mito-
chondria and nuclear DNA structure accompanied by
interference with reconstruction and replication of the
structures. At the tissue level elevated temperature leads
to impaired blood perfusion, caused by vessel embolism,
resulting in necrosis. High temperature alone permits to
obtain partial (>50%) or complete regression of the
tumor, in 30 and 15% of cases respectively. Unfortunately
the effect is short lasting. This may be explained by the
repair of lesions induced by elevated temperature after
the temperature is reduced back to the physiological
ranges. The thermotolerance phenomenon also seems
a relevant issue. Thermotolerance represents resistance to
elevated temperatures noted after 10 to 20 hours of incu-
bation in 37°C. Heat shock proteins are responsible for
this effect. Cells exposed within a short time (30-45 min)
to both elevated temperatures and ionising radiation
behave in a different manner: they become more sensitive
to ionising radiation. Radiobiolology explains the phe-
nomenon by a lower sensitivity to high temperatures
observed in G2 and M phases of the cell cycle. In contrast,
the radioresistant S phase is more sensitive to elevated
temperatures. Considering tumor cells to represent poor-
ly oxygenated and, thus, radioresistant tissue elements,
one finds them more sensitive to elevated temperatures,
which produce synergestic effects at the tissue level. As
compared to normal tissue, tumors with pathological vas-
cular supply may be more sensitive to vascular changes
provoked by increased temperature [1].
Practical aspects of hyperthermia application
The practical use of elevated temperature is still seen as
a kind of medical experiment even if the mechanism by
which it acts is more or less known. The main problem in
obtaining therapeutic ranges of temperature (42.5-48°C)
in the tumor involves the risk of exposing the neighbour-
ing healthy tissues to such temperatures. A variety of
techniques have been used to elevate tissue temperature.
Some authors used hot air or hot water, circulating inside
thin catheters inserted to the target tissue. More sophis-
ticated methods have involved heating of in-flowing blood
using the equipment for extra-corporeal circulation,
microwaves, ultrasound, radio waves. The last two tech-
niques seem to be the most effective and the most widely
practised. Reliable monitoring of temperature remains
a vital function in any hyperthermia system. Invention of
non-metallic thermometers and thermocouples, minia-
ture and resistant to noise effects, allows to establish the
temperature level in a simple and credible way. Till now,
most of the experience with clinical practice and applica-
tion of hyperthermia has been related to radiotherapy.
The combined therapeutic approach consists either of
hyperthermia and a second course of radiation therapy
(salvage radiotherapy with a limited radiation dose) or
primary radiotherapy of a standard dose, combined with
heating. In the first case, application of hyperthermia
opens up a chance for reducing the dose of radiation. In
many groups of patients, frequently with more than 100
subjects enrolled, with head and neck, skin, breast, gas-
trointestinal tract and urino-genitary tumors regression of
lesion was noted 1.5-2.5-fold more freqently after the
combined therapy, as compared to radiotherapy alone.
The most severe side effect of hyperthermia is risk of
thermal damage (burns) to the surrounding normal tissue.
The patient may also suffer from local discomfort caused
by elevated temperature during the treatment [1].
Method
Local hyperthermia was induced by an Ht-1 system developed at
the Gdaƒsk Institute of Technology. The system consisted of
a computer-controlled generator (500 kHz) with three amplifiers
which transmitted energy to the pathological tissue via a modi-
fied (electrically insulated) uterine brachytherapy applicator
(Fletcher – type, Nucletron). A colpostat served as an active
antenna to pass energy to the tissue. Its parts, including the
intrauterine probe and two vaginal applicators, could be con-
trolled separately by changing amplitudes and phases of trans-
mitted energy. Specific distributions of temperature could be
obtained, depending upon the patient’s clinical condition. Taking
into account the wave frequency (500 kHz), it is necessary to
apply a grounding electrode, which involved aluminium foil
wrapped around the patient’s pelvis. Temperature was moni-
tored by three thermocouples. Due to their small size (diameter
<0.5 mm), the temperature could be assessed, as indicated, in
the uterus, in direct vicinity of active antennas, in the anus, uri-
nary bladder and/or interstitially. Physical variables of the
induced waves (frequency, phase, power) and electrical imped-
ance of patient’s tissue were evaluated in a real time in accor-
dance with data obtained during the assessment of tempera-
ture distribution in “in vitro” experiments and computer simu-
lations [3]. During the procedure temperature of at least 42,5°C
in minimum 45 minutes was observed in the treated volume.
Total treatment time was 60-90 minutes. All parameters of each
procedures were recorded in the computer software.
Material
Ten patients were enrolled into the study. Eleven procedures
were performed: 9 in patients with uterine cervix cancer IIb and
IIIb FIGO stage, 2 in one patient with endometrial cancer. All
patients with cervical cancer were treated once and the patient
with endometial cancer received two procedures.
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According to the treatment protocol all the patients with
uterine cervix cancer were treated with external field irradia-
tion to the pelvis to the dose of 45-46 Gy (1.8-2 Gy/fraction).
Intracavitary LDR/HDR brachytherapy (dose of 45 Gy/point
“A” in two fractions) using colpostat for hyperthermia proce-
dure was then performed. In the case of the patient with
endometrial cancer case only LDR/MDR (dose 50 Gy/point “A”
in two fractions) brachytherapy was performed due to the
patient’s poor general condition. In every case informed consent
was obtained. Except for one case, when we observed equip-
ment failure, stable temperature was documented. In a few cases
the temperature of 48°C could be mantained and was well tol-
erated by the patients. In 10 cases no signs of intolerance were
observed, however in 2 cases a discomfort (verbalised as a sen-
sation of heat in the lower abdomen) forced us to lower the
power supplied by the amplifier. In one case a 1 x 0.5 cm thermal
lesion was accidentally induced due to contact of an inproperly
insulated part of the colpostat with the vaginal mucosa. This
lesion disappeared spontaneously. In none of the cases we had to
discontinue the treatment due to intolerance of the elevated
temperature.
Discussion
The basic limitations for a wider usage of hyperthermia as
a method adjuvant to radiotherapy is the lack of a simple
and effective way of obtaining elevated temperature
within the tumor only, at the same time sparing the
surrounding healthy tissues. Solving this problem seems
to be the easiest in the case of uterine neoplasms.
Unfavourable treatment results with radio- and radio-
chemotherapy call for developing new therapeutic
modalities. Several recently published papers show
a higher index of clinical effectivness after incorporating
hyperthermia into radiotherapy treatment. Some of the
most relevant are the results of the Dutch Deep
Hyperthermia Group. Their prospective, randomised,
multicentred based study analysed the treatment results of
358 patients with cervical, rectal and bladder cancer. In
this group 114 patients with cervical cancer were divided
into two subgroups – 58 patients received radiotherapy
and hyperthermia and 56 – radiotherapy alone. Local
control rates were 61% and 41%, respetively, with 3-year
survival time of 51% and 27% respectively – thus
statistically significant. In the subgroup of patients with
rectal cancer (143 pts) no statistically relevant difference
was observed but again, the ratio of local control was
16% and 8%, with 3-year survival 22% and 13%,
respectively. For the 101 patients with bladder cancer the
respective values were 42% versus 33% and 28% versus
22% [4]. It is very important to stress that these results
were obtained using “external heating”, which is not as
effective as intracavitary, due to treatment intolerance
and lower range of temperatures.
Van der Zee et al. observed skin reactions after
radiotherapy performed for breast cancer reccurence on
the thoracic wall. Two adjacent skin areas were irradiated
with the same dose, but in one field, additionally, hyper-
thermia was used. In the part of the skin which received
combined therapy significantly lesser teleangiectasiae
were observed. This phenomenon can be explained by
a faster reconstruction of radiation damaged blood vessel
endothelium [5].
In the randomised trial by Harima et al. assessing
the concentrations of Bax and Bcl-2 proteins in irradiated
cervical carcinoma cells significantly different protein
concentrations wetre found when hyperthermia was
applied together with radiotherapy versus radiotherapy
alone. This positively correlated with the ratio of com-
plete tumor regression (83.3% in the hyperthermia com-
bined group vs. 52.6% in the radiotherapy alone group).
Negative correlation was observed with lack of response
(5.6% vs. 21.1%, respectively) [6].
The queries concerning the adequate number of pro-
cedures seem to be solved by the results presented by
Valdagni et al [7] and Archangeli et al. [8]. No difference
was found when response rates were compared between 2
and 6 hyperthermia sessions, but 4 procedures were more
effective than one. This suggests 2 as the most reasonable
number of hyperthermia sessions.
Conclusions
All the experiences cited and described above provide
the background for future studies. More sophisticated
equipment allows to plan a more precise real-time tem-
perature distribution. We have planned further investi-
gations in order to definitely assess biological effect of
500 kHz intracavitary hyperthermia in cervical and
endometrial cancer patients. Hyperthermia tretment will
be performed as the single adjuvant modality between 7
amd 21 days before radical surgery. Each patient will
receive 2 hyperthermia sessions of at least 45 minutes
effective time of heating (>42.5°C). To avoid the effect of
thermotolerance treatment sessions will be separated by
at least a 48 hour gap. Histopathological examination
shall help to evaluate biological effectiveness and opti-
malization of treatment. The objectives of the trial will
include definition of how to practically include hyper-
thermia in radiation therapy, at least in selected groups of
patients (recurrences after primary irradiation or lack of
response to conventional radiotherapy).
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